Neurotech International Ltd News

Neurotech International Ltd: Positive Genomic Effects of NTI164 in PANDAS/PANS Patients

Nov 14 16:20 ET

Neurotech International Ltd: New Scientific Publication Highlights Benefits of NTI164

Nov 11 20:19 ET

Neurotech International Ltd: Neurotech Appoints Dr Anthony Filippis as MD/CEO

Nov 10 16:27 ET

Neurotech International Ltd: US FDA Response to Orphan Drug Request in PANDAS/PANS

Oct 3 18:52 ET

Neurotech International Ltd: Change of Director's Interest Notice

Sep 20 04:25 ET

Neurotech International Ltd: NTI164 Reverses Immune Dysregulation in PANDAS/PANS Children

Sep 8 19:00 ET

Neurotech International Ltd: Neurotech ESG Report

Aug 30 02:45 ET

Neurotech International Ltd: US FDA orphan drug designation requested for Rett Syndrome

Aug 29 18:49 ET

Neurotech International Ltd: Appendix 4G and Corporate Governance Statement

Aug 26 05:05 ET

Neurotech International Ltd: Neurotech Global Partnering and Registration Strategy

Aug 11 18:15 ET

Neurotech International Ltd: Further Significant Improvement in Rett Syndrome Patients

Jul 30 19:02 ET

Neurotech International Ltd: Quarterly Activities/Appendix 4C Cash Flow Report

Jul 24 19:07 ET

Neurotech International Ltd: Phase II/III autism trial shows further benefits

Jul 17 18:25 ET

Neurotech International Ltd: Significant improvement in Autism patients at 12 weeks

Jul 9 18:35 ET

Neurotech International Ltd: US FDA orphan drug designation requested for PANDAS/PANS

Jul 8 18:37 ET

Neurotech International Ltd: Appointment of Chief Medical Officer

Jul 4 18:44 ET

Neurotech International Ltd: Release of Shares from Voluntary Escrow

Jul 1 02:47 ET

Neurotech International Ltd: Expert PANDAS/PANS panel established post TGA meeting

Jun 27 19:16 ET

Neurotech International Ltd: Phase I/II Autism Patients Meet 2 Years of NTI164 Treatment

Jun 16 19:04 ET

Neurotech International Ltd: Further clinical benefit at 52 weeks in PANDAS/PANS patients

Jun 5 18:43 ET